Clinical trial
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated…
NCT00327262 · Central European Leukemia Study Group, Other · Unknown status
Key facts
| NCT number | NCT00327262 |
|---|---|
| Title | Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase |
| Official title | Multicenter, Phase III Study Comparing Imatinib (STI571, Glivec®) Standard Dose (400 Mg/Day) With Imatinib High Dose Induction (800 Mg/Day) Followed by Standard Dose Maintenance (400 Mg/Day) in Pretreated CML Patients in Chronic Phase |
| Lead sponsor | Central European Leukemia Study Group, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib |
| Enrollment | 240 |
| Start date | Jan 1, 2004 |
| Completion | Dec 1, 2008 |
| First posted | May 18, 2006 |
| Last update posted | Jun 20, 2006 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: